172 related articles for article (PubMed ID: 28123924)
1. CD73s protection of epithelial integrity: Thinking beyond the barrier.
Bowser JL; Broaddus RR
Tissue Barriers; 2016; 4(4):e1224963. PubMed ID: 28123924
[TBL] [Abstract][Full Text] [Related]
2. Loss of CD73-mediated actin polymerization promotes endometrial tumor progression.
Bowser JL; Blackburn MR; Shipley GL; Molina JG; Dunner K; Broaddus RR
J Clin Invest; 2016 Jan; 126(1):220-38. PubMed ID: 26642367
[TBL] [Abstract][Full Text] [Related]
3. Loss of CD73 shifts transforming growth factor-β1 (TGF-β1) from tumor suppressor to promoter in endometrial cancer.
Kurnit KC; Draisey A; Kazen RC; Chung C; Phan LH; Harvey JB; Feng J; Xie S; Broaddus RR; Bowser JL
Cancer Lett; 2021 May; 505():75-86. PubMed ID: 33609609
[TBL] [Abstract][Full Text] [Related]
4. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
5. CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.
Turcotte M; Allard D; Mittal D; Bareche Y; Buisseret L; José V; Pommey S; Delisle V; Loi S; Joensuu H; Kellokumpu-Lehtinen PL; Sotiriou C; Smyth MJ; Stagg J
Cancer Res; 2017 Oct; 77(20):5652-5663. PubMed ID: 28855210
[TBL] [Abstract][Full Text] [Related]
6. Ecto-5'-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature.
Yegutkin GG; Auvinen K; Rantakari P; Hollmén M; Karikoski M; Grénman R; Elima K; Jalkanen S; Salmi M
Eur J Immunol; 2015 Feb; 45(2):562-73. PubMed ID: 25402681
[TBL] [Abstract][Full Text] [Related]
7. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
Jin D; Fan J; Wang L; Thompson LF; Liu A; Daniel BJ; Shin T; Curiel TJ; Zhang B
Cancer Res; 2010 Mar; 70(6):2245-55. PubMed ID: 20179192
[TBL] [Abstract][Full Text] [Related]
8. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
9. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.
Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
J Clin Invest; 2020 Mar; 130(3):1185-1198. PubMed ID: 31770109
[TBL] [Abstract][Full Text] [Related]
10. CD73: a potent suppressor of antitumor immune responses.
Beavis PA; Stagg J; Darcy PK; Smyth MJ
Trends Immunol; 2012 May; 33(5):231-7. PubMed ID: 22487321
[TBL] [Abstract][Full Text] [Related]
11. CD73 plays a protective role in collagen-induced arthritis.
Chrobak P; Charlebois R; Rejtar P; El Bikai R; Allard B; Stagg J
J Immunol; 2015 Mar; 194(6):2487-92. PubMed ID: 25681339
[TBL] [Abstract][Full Text] [Related]
12. CD73: an emerging checkpoint for cancer immunotherapy.
Chen S; Wainwright DA; Wu JD; Wan Y; Matei DE; Zhang Y; Zhang B
Immunotherapy; 2019 Aug; 11(11):983-997. PubMed ID: 31223045
[TBL] [Abstract][Full Text] [Related]
13. Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73).
Snider NT; Altshuler PJ; Wan S; Welling TH; Cavalcoli J; Omary MB
Mol Biol Cell; 2014 Dec; 25(25):4024-33. PubMed ID: 25298403
[TBL] [Abstract][Full Text] [Related]
14. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.
Young A; Ngiow SF; Barkauskas DS; Sult E; Hay C; Blake SJ; Huang Q; Liu J; Takeda K; Teng MWL; Sachsenmeier K; Smyth MJ
Cancer Cell; 2016 Sep; 30(3):391-403. PubMed ID: 27622332
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD73 slows down migration of skin dendritic cells, affecting the sensitization phase of contact hypersensitivity reactions in mice.
Neuberger A; Ring S; Silva-Vilches C; Schrader J; Enk A; Mahnke K
J Dermatol Sci; 2017 Sep; 87(3):292-299. PubMed ID: 28743609
[TBL] [Abstract][Full Text] [Related]
16. CD73 contributes to anti-inflammatory properties of afferent lymphatic endothelial cells in humans and mice.
Eichin D; Pessia A; Takeda A; Laakkonen J; Bellmann L; Kankainen M; Imhof BA; Stoitzner P; Tang J; Salmi M; Jalkanen S
Eur J Immunol; 2021 Jan; 51(1):231-246. PubMed ID: 32970335
[TBL] [Abstract][Full Text] [Related]
17. CD73-adenosine: a next-generation target in immuno-oncology.
Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
[TBL] [Abstract][Full Text] [Related]
18. Adenosine Formed by CD73 on T Cells Inhibits Cardiac Inflammation and Fibrosis and Preserves Contractile Function in Transverse Aortic Constriction-Induced Heart Failure.
Quast C; Alter C; Ding Z; Borg N; Schrader J
Circ Heart Fail; 2017 Apr; 10(4):. PubMed ID: 28404626
[TBL] [Abstract][Full Text] [Related]
19. Ecto-5'-Nucleotidase (CD73) Deficiency in Mycobacterium tuberculosis-Infected Mice Enhances Neutrophil Recruitment.
Petit-Jentreau L; Jouvion G; Charles P; Majlessi L; Gicquel B; Tailleux L
Infect Immun; 2015 Sep; 83(9):3666-74. PubMed ID: 26150535
[TBL] [Abstract][Full Text] [Related]
20. Targeting cancer-derived adenosine: new therapeutic approaches.
Young A; Mittal D; Stagg J; Smyth MJ
Cancer Discov; 2014 Aug; 4(8):879-88. PubMed ID: 25035124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
